Beta-glucan (oat / barley)

Oat soluble fibre with an EU-authorised claim for lowering blood cholesterol at 3 g/day.

Evidence
Strong evidenceGRADE certainty: High
Typical dose
3 g/day of beta-glucan from oats or barley, typically met with ~75 g of oatmeal, ~40 g of oat bran, or a beta-glucan concentrate
Time to effect
LDL cholesterol changes typically over 4–6 weeks of consistent daily intake
Safety
Has documented cautions

Evidence ratings summarise published research on Beta-glucan (oat / barley) in general. They are not a health claim for any product and not advice for any individual. Talk to your doctor before starting anything new, especially if you take medication.

Ask about Beta-glucan (oat / barley)

Interactions

Taking any medication?

Check Beta-glucan (oat / barley) against it.

Why

Beta-glucan from oats holds an EU-authorised health claim for lowering blood cholesterol at 3 g/day. A meta-analysis of 28 RCTs found at least 3 g/day of oat beta-glucan lowered LDL cholesterol by about 0.25 mmol/L and total cholesterol by 0.30 mmol/L, with no significant effect on HDL or triglycerides. Support for barley beta-glucan comes from a NICE surveillance summary of meta-analyses.

How it works

Forms a viscous gel in the small intestine that binds bile acids, increasing their faecal loss and forcing hepatic cholesterol-to-bile conversion, lowering circulating LDL.

Expected onset · LDL cholesterol changes typically over 4–6 weeks of consistent daily intake

How to take

Dosage

3 g/day of beta-glucan from oats or barley (the EFSA-cited threshold), typically met with ~75 g of oatmeal, ~40 g of oat bran, or a beta-glucan concentrate.

Timing

With breakfast or any carbohydrate-containing meal

On the label

Look for products stating 'beta-glucan from oats' or 'beta-glucan from barley' with dose per serving, the EFSA claim requires the product to deliver at least 1 g per serving.

Studied in

Adults with elevated LDL cholesterol, aiming for a food-first approach.

Safety

Bloating and flatulence in the first 1–2 weeks as the colonic microbiota adapts. Can slow absorption of some medications. Separate dosing by 1–2 hours. Avoid in active inflammatory bowel disease flare (high-fibre may aggravate).
Loading interactions…

Evidence

At a glance

EU authorised claim: oat beta-glucan has been shown to lower blood cholesterol at 3 g/day. Whitehead 2014 Am J Clin Nutr meta-analysis (28 RCTs): at least 3 g/day of oat beta-glucan lowered LDL cholesterol by 0.25 mmol/L and total cholesterol by 0.30 mmol/L, with no significant effect on HDL or triglycerides.

GRADE certainty: High — EU authorised claim

Questions people ask

Does Beta-glucan (oat / barley) work?

EU authorised claim: oat beta-glucan has been shown to lower blood cholesterol at 3 g/day. Whitehead 2014 Am J Clin Nutr meta-analysis (28 RCTs): at least 3 g/day of oat beta-glucan lowered LDL cholesterol by 0.25 mmol/L and total cholesterol by 0.30 mmol/L, with no significant effect on HDL or triglycerides. Certainty of the evidence: High, EU authorised claim.

How is Beta-glucan (oat / barley) taken?

3 g/day of beta-glucan from oats or barley (the EFSA-cited threshold), typically met with ~75 g of oatmeal, ~40 g of oat bran, or a beta-glucan concentrate. Timing: With breakfast or any carbohydrate-containing meal. Ranges are those reported in the cited sources, not individual advice; talk to your doctor or pharmacist before starting, especially if you take medication.

Are there interactions or cautions?

Bloating and flatulence in the first 1–2 weeks as the colonic microbiota adapts. Can slow absorption of some medications. Separate dosing by 1–2 hours. Avoid in active inflammatory bowel disease flare (high-fibre may aggravate). Documented drug and supplement interactions can be looked up in the free interaction reference.

What is the evidence based on?

Sources: EFSA authorised claim Reg 432/2012, 'Oat beta-glucan has been shown to lower/reduce blood cholesterol' (3 g/day); Whitehead et al., Am J Clin Nutr 2014, oat beta-glucan and LDL meta-analysis; NICE guideline (2019): Cardiovascular disease: risk assessment and reduction, including lipid modification – CG181 (4-year surveillance evidence review, Appendix A).

One evidence finding a day, like this one: follow Healicus on Threads or Bluesky.